| A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor f | — | rekrutiert |
| A Non-interventional, Prospective Study With Benralizumab | — | rekrutiert |
| A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanc | Phase III | rekrutiert |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoc | Phase III | rekrutiert |
| A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With A | — | rekrutiert |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early | Phase III | rekrutiert |
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) | Phase II | rekrutiert |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acal | Phase III | rekrutiert |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 | Phase III | rekrutiert |
| ACCESS Registry: A Post Market Follow-up Study to Monitor the Safety, Performance and Usability | — | rekrutiert |
| BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatmen | — | rekrutiert |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello- | Phase III | rekrutiert |
| Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis | — | rekrutiert |
| Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Loca | Phase IV | rekrutiert |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Re | Phase IV | rekrutiert |
| CytOSorb TreatMent Of Critically Ill PatientS Registry | — | rekrutiert |
| Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligom | Phase II | rekrutiert |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in Peop | Phase III | rekrutiert |
| Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody | Phase III | rekrutiert |
| Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do N | Phase II | rekrutiert |
| Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia | Phase II | rekrutiert |
| Endometrial Cancer Lymphadenectomy Trial | ohne Phasenangabe | rekrutiert |
| E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe | — | rekrutiert |
| Filter Lifespan in Continuous Renal Replacement Therapy | — | rekrutiert |
| GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, T | — | rekrutiert |
| GMMG Multiple Myeloma Registry | — | rekrutiert |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multi | Phase III | rekrutiert |
| Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at | — | rekrutiert |
| Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator | — | rekrutiert |
| Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Ge | Phase III | rekrutiert |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-ne | Phase III | rekrutiert |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HE | Phase II | rekrutiert |
| PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced N | Phase II | rekrutiert |
| PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS | — | rekrutiert |
| PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and | — | rekrutiert |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial | Phase II / Phase III | rekrutiert |
| Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib | Phase III | rekrutiert |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase III | rekrutiert |
| Post-Marketing Surveillance of Vliwazell® Prowound Dressing | — | rekrutiert |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - POR | Phase III | rekrutiert |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add- | Phase III | rekrutiert |
| Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years Wi | — | rekrutiert |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR | Phase III | rekrutiert |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Folli | Phase III | rekrutiert |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Im | Phase III | rekrutiert |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination | Phase III | rekrutiert |
| Therapy Optimisation for the Treatment of Hairy Cell Leukemia | Phase II / Phase III | rekrutiert |